title: Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors.
abstract: GH concentration profiles in patients with acromegaly are characterized by rapid GH pulsatility and high interpulse GH concentrations. Animal and human studies have shown that GH pulses are consequent upon periodic discharges of hypothalamic GHRH, whereas interpulse GH levels might reflect tonic secretion of hypothalamic SRIH. Thus, the pattern of GH secretion in acromegaly may conceivably be attributed to high GHRH pulse frequency and/or SRIH deficiency. If this assumption is correct, removal of a GH-producing tumor should be followed by a persistently high GH pulse frequency and a high recurrence rate. We have studied pulsatile GH secretion in 12 patients with acromegaly before and after apparently complete removal of their pituitary tumors. Despite normalization of GH secretion after surgery, the disease recurred in 3 patients within 3 yr. The other 9 patients had normal insulin-like growth factor-I and basal and dynamic GH concentrations for 24 +/- 4 months postsurgery. Parameters of GH secretion in this group (pre- and postsurgery) were compared to sex-, age-, and body mass index-matched controls. Plasma GH concentrations in the postoperative and control series were analyzed by a chemiluminescent assay with a sensitivity of 0.01 micrograms/L. Removal of the somatotroph tumor led to normalization of mean and interpulse (but not the nadir) GH levels, pulse amplitude, and responses to GHRH. However, GH pulse frequency (14.2 +/- 1.2 vs. 11.8 +/- 0.9 pulses/24 h) did not change and was significantly (P < 0.001) higher than the control value (8.7 +/- 0.9 pulses/24 h). Thus, SRIH secretion in acromegaly is not inherently deficient, and high interpulse GH levels reflect the mass of tumorous somatotrophs. The persistence of rapid GH pulsatility in apparently "cured" patients with acromegaly suggests that abnormally rapid GHRH pulsatility may be an inherent component of the disease process.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Veterans Affairs Medical Center, Ann Arbor, Michigan 48109.
authors.forename: P J
authors.initials: PJ
authors.lastname: Ho
authors.forename: C A
authors.initials: CA
authors.lastname: Jaffe
authors.forename: R D
authors.initials: RD
authors.lastname: Friberg
authors.forename: W F
authors.initials: WF
authors.lastname: Chandler
authors.forename: A L
authors.initials: AL
authors.lastname: Barkan
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D000328:Adult; D000367:Age Factors; D000368:Aged; D000818:Animals; D002940:Circadian Rhythm; D005260:Female; D005500:Follow-Up Studies; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000378:metabolism; D008163:Luminescent Measurements; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010911:Pituitary Neoplasms / Q000097:blood* / Q000503:physiopathology / Q000601:surgery*; D011336:Probability; D012016:Reference Values; D012680:Sensitivity and Specificity; D012727:Sex Characteristics; D013004:Somatostatin / Q000378:metabolism; D013997:Time Factors
chemical_list: D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone